- Rheumatoid Arthritis Slideshow Pictures
- Take the RA Quiz
- Joint-Friendly Exercises to Reduce RA Pain Slideshow
Does Arava (leflunomide) cause side effects?
Arava reduces inflammation in the joints that is responsible for both the symptoms of rheumatoid arthritis and the destruction of joints. This reduces symptoms as well as the progressive deformities of the joints caused by the arthritis.
Arava reduces inflammation by suppressing the activity of immune cells responsible for the inflammation. Arava suppresses immune cells by inhibiting dihydroorotate dehydrogenase, an enzyme that is necessary for the production of DNA and RNA.
Without DNA and RNA the immune cells (and most other types of cells) cannot multiply or function (or exist). Because of its unique and different mechanism of action, Arava is of value when added to other medications used for treating rheumatoid arthritis.
Common side effects of Arava include
Serious side effects of Arava include
- high blood pressure,
- chest pain,
- abnormal heartbeats,
- increased risk of infections since Arava suppresses the immune system, and
- fatal liver failure.
Rifampin increases the blood concentration of the active form of Arava by 40% probably by increasing the conversion of Arava to its active form. This may increase the side effects of Arava.
Increased activity of warfarin by Arava has been reported rarely.
Arava also may increase the blood concentration of tolbutamide.
Arava is harmful to the developing fetus and should not be used during pregnancy.
What are the important side effects of Arava (leflunomide)?
The most frequently reported side effects are:
Other important side effects of leflunomide include:
Since leflunomide suppresses the immune system, it may increase the risk to patients of infections. The most frequently reported infections involve the respiratory tract. Leflunomide may cause fatal liver failure. More often it causes abnormal liver tests in the blood, suggesting damage to the liver. The liver tests usually return to normal with continued treatment.
The dose of leflunomide should be reduced if liver tests are persistently greater than twice the upper limit of normal, and leflunomide should be discontinued if the levels remain above three times the upper limit of normal despite a reduction in dose. Leflunomide should not be administered to individuals with liver problems.
Arava (leflunomide) side effects list for healthcare professionals
The following serious adverse reactions are described elsewhere in the labeling:
- Bone marrow suppression
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Peripheral neuropathy
- Interstitial lung disease
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In clinical studies (Trials 1, 2, and 3), 1,865 patients were treated with Arava administered as either monotherapy or in combination with methotrexate or sulfasalazine. Patients ranged in age from 19 to 85 years, with an overall median age of 58 years. The mean duration of RA was 6 years ranging from 0 to 45 years.
Elevation of Liver Enzymes
Treatment with Arava was associated with elevations of liver enzymes, primarily ALT and AST, in a significant number of patients; these effects were generally reversible. Most transaminase elevations were mild ( ≤ 2-fold ULN) and usually resolved while continuing treatment. Marked elevations ( > 3-fold ULN) occurred infrequently and reversed with dose reduction or discontinuation of treatment.
Table 1 shows liver enzyme elevations seen with monthly monitoring in clinical trials Trial 1 and Trial 2. It was notable that the absence of folate use in Trial 3 was associated with a considerably greater incidence of liver enzyme elevation on methotrexate.
Table 1: Liver Enzyme Elevations > 3-fold Upper
Limits of Normal (ULN) in Patients with RA in Trials 1, 2, and 3**
|Trial 1||Trial 2||Trial 3*|
|Arava 20 mg/day
|MTX 7.5 - 15 mg/wk
|SSZ 2.0 g/day
|Arava 20 mg/day
|MTX 7.5 - 15 mg/wk
|ALT (SGPT) > 3-fold ULN (n %)||8 (4.4)||3 (2.5)||5 (2.7)||2 (1.5)||1 (1.1)||2 (1.5)||13 (2.6)||83 (16.7)|
|Reversed to ≤ 2-fold ULN:||8||3||5||2||1||2||12||82|
|Timing of Elevation|
|MTX = methotrexate, PL =
placebo, SSZ = sulfasalazine, ULN = Upper limit of normal
*Only 10% of patients in Trial 3 received folate. All patients in Trial 1 received folate.
In a 6 month study of 263 patients with persistent active rheumatoid arthritis despite methotrexate therapy, and with normal LFTs, Arava was administered to a group of 130 patients starting at 10 mg per day and increased to 20 mg as needed. An increase in ALT greater than or equal to three times the ULN was observed in 3.8% of patients compared to 0.8% in 133 patients continued on methotrexate with placebo.
Most Common Adverse Reactions
The most common adverse reactions in Arava-treated patients with RA include diarrhea, elevated liver enzymes (ALT and AST), alopecia and rash. Table 2 displays the most common adverse reactions in the controlled studies in patients with RA at one year ( ≥ 5% in any Arava treatment group).
Table 2: Percentage Of Patients With Adverse Events ≥ 5% In Any
Group in all RA Studies in Patients with RA
|Placebo-Controlled Trials||Active-Controlled Trials||All RA Studies|
|Trial 1 and 2||Trial 3 1|
|Arava 20 mg/day
|MTX 7.5 - 15 mg/wk
|Arava 20 mg/day
|MTX 7.5 - 15 mg/wk
|Abnormal Liver Enzymes||10%||2%||4%||10%||6%||17%||5%|
|MTX = methotrexate, PL =
placebo, SSZ = sulfasalazine
1 Only 10% of patients in Trial3 received folate. All patients in Trial 1 received folate; none in Trial 2 received folate.
2 Includes all controlled and uncontrolled trials with Arava (duration up to 12 months).
3Hypertension as a preexisting condition was overrepresented in all Arava treatment groups in phase III trials
Adverse events during a second year of treatment with Arava in clinical trials were consistent with those observed during the first year of treatment and occurred at a similar or lower incidence.
Less Common Adverse Reactions
In addition, in controlled clinical trials, the following adverse events in the Arava treatment group occurred at a higher incidence than in the placebo group. These adverse events were deemed possibly related to the study drug.
Blood and Lymphatic System: leukocytosis, thrombocytopenia;
Eye: blurred vision, eye disorder, papilledema, retinal disorder, retinal hemorrhage;
General Disorders: malaise;
Immune System: anaphylactic reaction;
Respiratory System: dyspnea;
Post Marketing Experience
The following additional adverse reactions have been identified during postapproval use of Arava. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System: agranulocytosis, leukopenia, neutropenia, pancytopenia;
Infection: opportunistic infections, severe infections including sepsis;
Immune System: angioedema;
Nervous system: peripheral neuropathy;
Skin and Appendages: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis including cutaneous necrotizing vasculitis, cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis.
What drugs interact with Arava (leflunomide)?
Following oral administration, leflunomide is metabolized to an active metabolite, teriflunomide, which is responsible for essentially all of leflunomide's in vivo activity. Drug interaction studies have been conducted with both Arava (leflunomide) and with its active metabolite, teriflunomide, where the metabolite was directly administered to the test subjects.
Effect of Potent CYP and Transporter Inducers
- Leflunomide is metabolized by CYP450 metabolizing enzymes.
- Concomitant use of Arava and rifampin, a potent inducer of CYP and transporters, increased the plasma concentration of teriflunomide by 40%.
- However, when co-administered with the metabolite, teriflunomide, rifampin did not affect its pharmacokinetics.
- No dosage adjustment is recommended for Arava when coadministered with rifampin.
- Because of the potential for Arava concentrations to continue to increase with multiple dosing, caution should be used if patients are to be receiving both Arava and rifampin.
Effect on CYP2C8 Substrates
- Teriflunomide is an inhibitor of CYP2C8 in vivo.
- In patients taking Arava, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased.
- Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required.
Effect on Warfarin
- Coadministration of Arava with warfarin requires close monitoring of the international normalized ratio (INR) because teriflunomide, the active metabolite of Arava, may decrease peak INR by approximately 25%.
Effect on oral Contraceptives
- Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel.
- Consideration should be given to the type or dose of contraceptives used in combination with Arava.
Effect on CYP1A2 Substrates
- Teriflunomide, the active metabolite of Arava, may be a weak inducer of CYP1A2 in vivo.
- In patients taking Arava, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced.
- Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required.
Effect on Organic Anion Transporter 3 (OAT3) Substrates
- Teriflunomide inhibits the activity of OAT3 in vivo.
- In patients taking Arava, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.
- Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required.
Effect on BCRP and Organic Anion Transporting Polypeptide B1 and B3 (OATP1B1/1B3) Substrates
- Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo.
- For a patient taking Arava, the dose of rosuvastatin should not exceed 10 mg once daily.
- For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking Arava.
Multimedia: Slideshows, Images & Quizzes
What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis
What is rheumatoid arthritis (RA)? Learn about treatment, diagnosis, and the symptoms of juvenile rheumatoid arthritis. Discover...
Rheumatoid Arthritis Exercises: Joint-Friendly Workouts
Regular exercise boosts fitness and helps reverse joint stiffness for people with rheumatoid arthritis (RA). WebMD demonstrates...
Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?
How is rheumatoid arthritis different from other forms of arthritis, such as osteoarthritis and gout? Take the Rheumatoid...
Famous Faces With Rheumatoid Arthritis
Learn more about the famous faces of rheumatoid arthritis such as Lucille Ball, Glenn Frey, and more.
Related Disease Conditions
Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, the tissue around the joints, as well as other organs in the body. Because it can affect multiple other organs of the body, rheumatoid arthritis is referred to as a systemic illness and is sometimes called rheumatoid disease. The 16 characteristic early RA signs and symptoms include the following. Anemia Both sides of the body affected (symmetric) Depression Fatigue Fever Joint deformity Joint pain Joint redness Joint stiffness Joint swelling Joint tenderness Joint warmth Limping Loss of joint function Loss of joint range of motion Many joints affected (polyarthritis)
16 Early Rheumatoid Arthritis (RA) Symptoms and Signs
Early RA symptoms and signs vary differently from person to person. The most common body parts that are initially affected by RA include the small joints of the hands, wrists, and feet, and the knees and hip joints. Joint inflammation causes stiffness. Warmth, redness, and pain may vary in degree.
Rheumatoid Arthritis vs. Fibromyalgia
Though rheumatoid arthritis (RA) and fibromyalgia have similar symptoms, RA is an autoimmune disease and fibromyalgia is a chronic pain syndrome. RA symptoms include joint redness, swelling, and pain that lasts more than six weeks. Fibromyalgia symptoms include widespread pain, tingling feet or hands, depression, and bowel irritability. Home remedies for both include stress reduction, exercise, and getting enough sleep.
Pain Management and Rheumatoid Arthritis
Second Source article from WebMD
Second Source article from Government
Can Rheumatoid Arthritis Be Caused by Stress?
Rheumatoid arthritis is a chronic inflammatory joint condition and an autoimmune disease. At times, treatment can make rheumatoid arthritis symptoms (pain and swelling) disappear for a while. This symptom-free period is referred to as “remission.” A remission is followed by the reappearance of symptoms and this period is known as a flare-up. Research says that rheumatoid arthritis can be caused by stress.
Rheumatoid Arthritis vs. Arthritis
Arthritis is a general term used to describe joint disease. Rheumatoid arthritis (RA) is a type of arthritis in which the body’s immune system mistakenly attacks the joints, causing chronic inflammation.
How Serious Is Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that typically affects the joints and other body parts, such as the skin, eyes, lungs, heart and blood vessels. RA is an autoimmune disorder, a condition where the body’s immune system attacks its own tissues. If not diagnosed early and appropriately treated, RA can lead to permanent deformities, disabilities and serious systemic complications.
Juvenile Rheumatoid Arthritis (JRA)
Juvenile rheumatoid arthritis (JRA) annually affects one child in every thousand. There are six types of JRA. Treatment of juvenile arthritis depends upon the type the child has and should focus on treating the symptoms that manifest.
What Are the Four Stages of Rheumatoid Arthritis?
Rheumatoid arthritis is a chronic inflammatory disease characterized by pain and inflammation in joints, typically of the hands and feet. It is an autoimmune disease in which the immune system of the body attacks its own healthy cells, resulting in inflammation of the membrane lining the joints and damage to joint tissue.
Breastfeeding With Rheumatoid Arthritis
You can breastfeed your baby even if you have rheumatoid arthritis (RA). However, you must always consult your doctor before you start the process.
Safest Rheumatoid Arthritis Drugs During Pregnancy
None of the drugs used in the treatment of rheumatoid arthritis (RA) is completely safe during pregnancy. You must discuss with your physician regarding the decision to use, modify, or stop any medications.
Osteoarthritis vs. Rheumatoid Arthritis
Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic joint disorders. RA is also an autoimmune disease. OA and RA symptoms and signs include joint pain, warmth, and tenderness. Over-the-counter pain relievers treat both diseases. There are several prescription medications that treat RA.
Can Rheumatoid Arthritis Affect Pregnancy?
Yes, rheumatoid arthritis (RA) affects pregnancy. RA can lead to complications like preterm birth, raised blood pressure (preeclampsia), and low birth weight babies.
Causes of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disorder (the body’s immune system mistakenly attacks its own cells). Certain factors increase the risk of RA.
Treatment & Diagnosis
- Rheumatoid Arthritis FAQs
- Rheumatoid Arthritis vs. Osteoarthritis
- Rheumatoid Arthritis (RA): 17 Warning Signs of Serious Complications
- Is HCQ Safe For Pregnant Women With Rheumatoid Arthritis (RA)?
- Why Does Pregnancy Affect the Course of Rheumatoid Arthritis (RA)?
- Can Rituximab Be Taken By Breastfeeding Women With Rheumatoid Arthritis?
- Are Corticosteroids Safe for Pregnant and Nursing Women with Rheumatoid Arthritis?
- Is Anakinra (Kineret) Safe for Pregnant Women with Rheumatoid Arthritis (RA)?
- How Does Pregnancy Affect the Course of Rheumatoid Arthritis (RA)?
- What if I get COVID-19 with Rheumatoid Arthritis?
- Patient Story: Rheumatoid Arthritis Symptoms
- Rheumatoid Arthritis Joint Symptoms and Signs: What Do They Mean?
- Rheumatoid Arthritis: Which Patients Do Best?
- 5 Surprising Facts About Rheumatoid Arthritis
- Patient Story: Rheumatoid Arthritis and Pregnancy
- Rheumatoid Arthritis: Questions for Your Doctor
- Kineret (anakinra) for Rheumatoid Arthritis
- Treatment Update on Rheumatoid Arthritis
- Psoriasis, Lupus, Rheumatoid Arthritis Share One Gene
- Rheumatoid Arthritis & Diabetes Gene (PTPN22)
- Arava Approved For Rheumatoid Arthritis
- Smoking: A New Risk - Rheumatoid Arthritis
- Cox-2 Inhibitors, What's Next? - Expert Panel Votes
- Ultrasound Imaging of Joints in Rheumatoid Arthritis (RA)
- Living With Rheumatoid Arthritis
- Is Inflammatory Arthritis the Same as Rheumatoid Arthritis?
- Can Milk Allergy Cause Rheumatoid Arthritis?
- What Are the Side Effects of Remicade for Rheumatoid Arthritis?
- Should You Avoid Drinking Soda with Rheumatoid Arthrits?
- Are Hidradenitis and Rheumatoid Arthritis Related?
- Does Lipitor Help Rheumatoid Arthritis?
- Will Rheumatoid Arthritis Nodules Go Away?
- What's the Rheumatoid Arthritis Prognosis?
- What Are Home Remedies for Rheumatoid Arthritis?
- Patient Story: Rheumatoid Arthritis Treatment
- Rheumatoid Arthritis: Living With a Chronic Disease
- Rheumatoid Arthritis - Checking Your Pulse Audio Segment
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.